Biogen Inc.

NASDAQ Global Select
Back to all articles
Bearish -65

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB - PR Newswire

📉 Biogen's stock price fell $13.16 (6.43%) to close at $191.37 on May 14, 2026.

🧪 The Phase 2 CELIA study for diranersen (BIIB080) missed its primary dose-response endpoint despite being described as 'compelling'.

⚖️ Pomerantz Law Firm is investigating claims of securities fraud and unlawful business practices against Biogen Inc. and its officers.

📅 The investigation was prompted by the May 14, 2026 press release regarding the failed clinical trial primary endpoint.

👥 Investors are advised to contact Danielle Peyton at Pomerantz LLP to join the class action investigation.

🏢 Pomerantz LLP is a premier firm in corporate and securities litigation with offices globally.

Risk Factors
  • Biogen's stock price dropped $13.16 per share, or 6.43%, immediately following the announcement of missed clinical trial results.
  • The Phase 2 CELIA study for diranersen (BIIB080) failed to meet its primary dose-response endpoint, undermining the 'compelling' nature of the results claimed by management.
  • Pomerantz Law Firm is actively investigating claims that Biogen and its officers engaged in securities fraud or other unlawful business practices related to the clinical trial disclosures.
  • An active class action investigation suggests potential legal liabilities and reputational damage for Biogen Inc. regarding the accuracy of their previous communications.
Full Analysis
Pomerantz Law Firm is investigating potential securities fraud and unlawful business practices on behalf of investors of Biogen Inc. (NASDAQ: BIIB). The firm advises affected investors to contact their legal team regarding these claims, highlighting the firm's extensive history in corporate and securities litigation. The investigation stems from a specific event on May 14, 2026, when Biogen released top-line results for its Phase 2 CELIA study evaluating diranersen (BIIB080) for early Alzheimer's disease. Although the company characterized the findings as compelling, the study failed to meet its primary dose-response endpoint. Following the announcement of the missed clinical endpoint, Biogen's stock price dropped significantly by $13.16 per share, or 6.43%, closing at $191.37 on May 14, 2026. This sharp decline in market value has prompted the current legal inquiry into whether prior disclosures constituted securities fraud. The article serves as an investor alert detailing the specific allegations of misconduct related to the clinical trial results and the subsequent financial impact on shareholders. It provides contact information for Danielle Peyton at Pomerantz LLP for investors wishing to join the class action investigation.